Checkpoint Capital’s Trevi Therapeutics TRVI Stock Holding History

Checkpoint Capital’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.4M	Buy	75,000 +25,000	+50%	+$364K	0.36%	6
2026 Q1	$597K	Buy	+50,000	New	+$560K	0.21%	8
2025 Q1	–	Sell	-1,084,135	Closed	-$4.47M	–	20
2024 Q4	$4.47M	Buy	1,084,135 +834,135	+334%	+$2.67M	2.27%	11
2024 Q3	$835K	Sell	250,000 -250,089	-50%	-$743K	0.41%	15
2024 Q2	$1.49M	Sell	500,089 -5,993	-1%	-$16.7K	0.9%	13
2024 Q1	$1.75M	Sell	506,082 -786,234	-61%	-$1.75M	1.17%	14
2023 Q4	$1.73M	Buy	+1,292,316	New	+$1.96M	1.05%	14

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Checkpoint Capital's TRVI Position: Q2 2026 in Review

Checkpoint Capital increased its Trevi Therapeutics (TRVI) stake by 50% in Q2 2026, buying an estimated $364K and bringing the position to 75,000 shares worth $1.4M. The position accounts for 0.36% of the portfolio, ranked #6.

Checkpoint Capital first reported a position in TRVI in Q4 2023 and has held it in 7 quarters since. The position peaked at $4.47M in Q4 2024. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

Checkpoint Capital held 75,000 shares of Trevi Therapeutics worth $1.4M as of Q2 2026.
Checkpoint Capital bought 25,000 Trevi Therapeutics shares in Q2 2026, an estimated $364K.
Trevi Therapeutics made up 0.36% of Checkpoint Capital's portfolio in Q2 2026, its #6 holding.
Checkpoint Capital first reported a position in Trevi Therapeutics in Q4 2023 and has held it in 7 quarters since.
Checkpoint Capital's Trevi Therapeutics position peaked at $4.47M in Q4 2024.
218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Checkpoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.